Qijun Qian

Shanghai University — China

Biochemistry, Genetics and Molecular Biology · Life Sciences

33h-index3.6kcitations228works1.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(114), CAR-T cell therapy research(58), Viral Infectious Diseases and Gene Expression in Insects(57), Cancer Research and Treatments(52), RNA Interference and Gene Delivery(34)

Publications228 total

Lymphodepletion-free jl-lightning CAR-T targeting CD19/CD22/BCMA achieved 100% CR in 3 Relapsed/Refractory B-NHL patients: A lymphodepletion regimen comparison study
Blood·2025Open Access
958 CT224: a novel biparatopic VHH-based CDH17×CD3 T cell engager optimized for safety and efficacy in colorectal cancer
Regular and Young Investigator Award Abstracts·2025Open Access
976 CT111, a PD-1 x CTLA-4 x VEGF trispecific antibody, demonstrates potent anti-tumor efficacy through synergistic immune checkpoint blockade and VEGF inhibition with cooperative avidity
Regular and Young Investigator Award Abstracts·2025Open Access
Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies
Advanced Science·2025· 1 citedOpen Access
Engineering of <i>BZ</i> transposase and transposon donor vector for enhanced efficiency and safety in gene delivery applications
Nucleic Acids Research·2025· 1 citedOpen Access
Cryopreserved leukapheresis enables scalable and distributed CAR-T manufacturing: a multi-platform comparative study
Scientific Reports·2025· 2 citedOpen Access
Gut-brain axis in post-traumatic stress disorder: microbial - mediated mechanisms and new therapeutic approaches - A narrative review
Frontiers in Pharmacology·2025· 3 citedOpen Access
IPSC‑derived NK cells for immunotherapy and therapeutic perspective (Review)
Molecular Medicine Reports·2025· 10 citedOpen Access
Safety and efficacy of non-viral aPD1-MSLN JL-lightning–CAR-T in advanced malignant mesothelioma in a phase I trial.
Journal of Clinical Oncology·2025· 1 cited
Abstract 5465: A novel CD3 VHH—based multi-specific T cell engager platform and multiple leads for gastric cancer and auto-immune disease
Cancer Research·2025· 1 cited
Abstract 3173: JL-lightning CAR-T, a next generation non-viral CAR-T without <i>in-vitro</i> culturing procedure, shows high clinical efficacy, good safety with low treatment dosage
Cancer Research·2025
Comparative analysis and process optimization for manufacturing CAR-T using the PiggyBac system derived from cryopreserved versus fresh PBMCs
Scientific Reports·2025· 5 citedOpen Access
Unleashing the potential of a low CpG Passer transposon for superior CAR-T cell therapy
Frontiers in Immunology·2025· 1 citedOpen Access
Minimized antibiotic-free plasmid vector for gene therapy utilizing a new toxin-antitoxin system
Metabolic Engineering·2023· 8 cited
Safety, efficacy, and biomarker analysis of response to engineered tumor-infiltrating lymphocytes secreting anti-PD-1 antibody in recurrent glioblastoma: An open-label, two-arms, phase 1 study.
Journal of Clinical Oncology·2023· 6 cited
Abstract CT134: Non-viral mesothelin-targeted CAR-T cells armored with IFNg-induced secretion of PD-1 nanobody in treatment of malignant mesothelioma in phase I clinical trial
Cancer Research·2023· 8 cited
Data from Effective gene-viral therapy of leukemia by a new fiber chimeric oncolytic adenovirus expressing TRAIL: &lt;i&gt;in vitro&lt;/i&gt; and &lt;i&gt;in vivo&lt;/i&gt; evaluation
2023Open Access
Supplementary Fig. S1 from Effective gene-viral therapy of leukemia by a new fiber chimeric oncolytic adenovirus expressing TRAIL: &lt;i&gt;in vitro&lt;/i&gt; and &lt;i&gt;in vivo&lt;/i&gt; evaluation
2023Open Access
Supplementary Fig. S1 from Effective gene-viral therapy of leukemia by a new fiber chimeric oncolytic adenovirus expressing TRAIL: &lt;i&gt;in vitro&lt;/i&gt; and &lt;i&gt;in vivo&lt;/i&gt; evaluation
2023Open Access
Data from Effective gene-viral therapy of leukemia by a new fiber chimeric oncolytic adenovirus expressing TRAIL: &lt;i&gt;in vitro&lt;/i&gt; and &lt;i&gt;in vivo&lt;/i&gt; evaluation
2023Open Access
page 1 of 12Next →

Frequent Co-authors

Huajun Jin(13), Xinyuan Liu(13), Changqing Su(12), Mengchao Wu(11), Zhenlong Ye(9), Cheng Qian(6), Linfang Li(6), Zenghui Xu(5), Duqing Jiang(5), Yao Huang(5), Hongping Wu(5), Ying Wang(5), Yongmei Ding(4), Jinfa Gu(4), Linfang Li(4), Lianzhen Cui(4), Min Ding(4), Qi Zhang(4), Jonathan S. T. Sham(4), Huibin Xue(4)